Selected markers of ovarian cancer and their relation to targeted therapy (Review).
Exp Ther Med
; 27(5): 236, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38628658
ABSTRACT
Despite advances in surgical treatment techniques and chemotherapy-including anti-angiogenic and immune poly (ADP-ribose) polymerase inhibitors, the 5-year survival rate in ovarian cancer (OC) remains low. The reasons for this are the diagnosis of cancer in advanced clinical stages, chemoresistance and cancer recurrence. New therapeutic approaches are being developed, including the search for new biomarkers that are also targets for targeted therapy. The present review describes new molecular markers with relevance to targeted therapy, which to date have been studied only in experimental research. These include the angiogenic protein angiopoietin-2, the transmembrane glycoprotein ectonucleotide pyrophosphatase/phosphodiesterase 1, the adhesion protein E-cadherin, the TIMP metallopeptidase inhibitor 1 and Kruppel-like factor 7. Drugs affecting cancer stem cells (CSCs) in OC, such as metformin and salinomycin, as well as inhibitors of CSCs markers aldehyde dehydrogenase 1 (with the drug ATRA) and the transcription factor Nanog homeobox (microRNA) are also discussed. A new approach to prevention and possible therapies under investigation such as development of vaccines containing a subpopulation of CD117(+) and CD44(+) stem cells with a promising option for use in women with OC was described.
E-cadherin; Kruppel like factor 7; Nanog homeobox; TIMP metallopeptidase inhibitor 1; aldehyde dehydrogenase 1 family member A1; angiopoietin-2; cancer stem cells; ectonucleotide pyrophosphatase/phosphodiesterase 1; endothelial cell-specific molecule 1; markers; ovarian cancer; sodium-dependent phosphate transport protein 2B; vaccines containing CSCs
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article